CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CD8(+) T-cell immunity orchestrated by iNKT cells.
CD8(+) T-cell immunity orchestrated by iNKT cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
属于适应性免疫系统的CD8+ T细胞在防御病毒感染和癌症中发挥关键作用。当前基于CD8+ T细胞的免疫疗法已成为根除肿瘤细胞并长期预防其在血液系统恶性肿瘤中复发的优越治疗途径。人们认为,有效的适应性免疫应答关键依赖于固有免疫部分的帮助。恒定自然杀伤T(iNKT)细胞是先天样T淋巴细胞,被认为是最早对感染作出应答的细胞之一,能够分泌大量多种细胞因子和趋化因子,从而广泛调节固有免疫和适应性免疫应答者。与CD8+ T细胞一样,iNKT细胞也在防御细胞内病原体感染和癌症中发挥重要作用。在这篇综述中,我们将讨论由iNKT细胞贡献的CD8+ T细胞免疫,包括iNKT细胞介导的交叉致敏和记忆形成,并讨论我们对于记忆CD8+ T细胞分化机制以及衰老诱导的T细胞免疫损伤理解的最新进展。
CD8 + T cells belonging to the adaptive immune system play key roles in defending against viral infections and cancers. The current CD8 + T cell-based immunotherapy has emerged as a superior therapeutic avenue for the eradication of tumor cells and long-term prevention of their recurrence in hematologic malignancies. It is believed that an effective adaptive immune response critically relies on the help of the innate compartment. Invariant natural killer T (iNKT) cells are innate-like T lymphocytes that have been considered some of the first cells to respond to infections and can secrete a large amount of diverse cytokines and chemokines to widely modulate the innate and adaptive immune responders.
Like CD8 + T cells, iNKT cells also play an important role in defense against intracellular pathogenic infections and cancers. In this review, we will discuss the CD8 + T-cell immunity contributed by iNKT cells, including iNKT cell-mediated cross-priming and memory formation, and discuss recent advances in our understanding of the mechanisms underlying memory CD8 + T-cell differentiation, as well as aging-induced impairment of T-cell immunity.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。